- According to Inserm, only 1.2 to 2% of Alzheimer’s cases are hereditary.
- According to Inserm, out of 25 patients, 10 are men and 15 are women.
This could be the first step in curing Alzheimer’s disease. According to researchers, a drug normally given to patients with type 2 diabetes could slow cognitive decline in older people, particularly those with disorders or pathologies such as Alzheimer’s disease. Your work has just been published in the magazine Journal of Neurology.
A link between insulin resistance in the brain and cognitive decline
To arrive at this conclusion, researchers at the Beth Israel Deaconess Medical Center in Boston, USA, assumed that insulin resistance in the brain could be linked to cognitive decline. So they wanted to test the impact that treating diabetes could have on brain health.
Three groups of participants…
During their experiment, they divided the patients into three groups. The first two received an insulin-based medication to treat diabetes in the form of a nasal spray for 24 weeks. In group 1, the patients were diabetic, but not in group 2. Finally, the participants in the third group received a placebo.
Better outcomes in those who received insulin treatment
At the end of their clinical study, the scientists found that the patients in Group 1 performed better on cognitive tests than they did without the drug. They also had a faster gait. On the other hand, in patients in Group 2 who were not diabetic but were taking the drug, the researchers noticed an improvement in their verbal memory and decision-making, which was not the case in Group 3.
Prevent or slow the progression of dementia associated with Alzheimer’s disease
“The consistency of data trends showing better performance in walking speed and cognition in participants treated with intranasal insulin, particularly in those with prediabetes, has broad implications for possible early intervention with intranasal insulin in this population to reduce progression to dementia to prevent or slow down Alzheimer’s disease‘ believes Long Ngo, one of the lead authors of the study.
Towards a treatment for Alzheimer’s disease
The scientists now intend to continue their research to confirm that this treatment is safe for patients with cognitive disorders. A discovery that could well be revolutionary. In fact, there is currently no treatment that can cure or stop the progression of Alzheimer’s disease. However, it remains the most common neurodegenerative pathology in France, affecting more than 1.2 million people, according to reports Health insurance.